4.6 Article

Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience

Related references

Note: Only part of the references are listed.
Review Allergy

Immunogenicity of Anti-TNF-α Agents in Autoimmune Diseases

Nadia Emi Aikawa et al.

CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2010)

Article Gastroenterology & Hepatology

Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland

Evangelos A. Russo et al.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2010)

Article Gastroenterology & Hepatology

Adalimumab for Crohn's Disease in Clinical Practice at Mayo Clinic: The First 118 Patients

Jason M. Swoger et al.

INFLAMMATORY BOWEL DISEASES (2010)

Article Gastroenterology & Hepatology

Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naive patients

A. Swaminath et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)

Article Gastroenterology & Hepatology

Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience

A. Oussalah et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)

Review Gastroenterology & Hepatology

Does smoking reduce infliximab's effectiveness against Crohn's disease?

Neeraj Narula et al.

CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2009)

Article Gastroenterology & Hepatology

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

Konstantinos Karmiris et al.

GASTROENTEROLOGY (2009)

Article Gastroenterology & Hepatology

Mucosal Healing Predicts Long-term Outcome of Maintenance Therapy with Infliximab in Crohn's Disease

Fabian Schnitzler et al.

INFLAMMATORY BOWEL DISEASES (2009)

Article Gastroenterology & Hepatology

Mucosal cytokine network in inflammatory bowel disease

Akira Andoh et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2008)

Article Gastroenterology & Hepatology

The use of adalimumab in the management of refractory Crohn's disease

G. -T. Ho et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)

Article Gastroenterology & Hepatology

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial

W. J. Sandborn et al.

Article Medicine, General & Internal

Adalimumab induction therapy for Crohn disease previously treated with infliximab - A randomized trial

William J. Sandborn et al.

ANNALS OF INTERNAL MEDICINE (2007)

Article Gastroenterology & Hepatology

Adalimumab in patients with Crohn's disease -: safety and efficacy in an open-label single centre study

J. Seiderer et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)

Article Gastroenterology & Hepatology

Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study

L. Peyrin-Biroulet et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)

Article Gastroenterology & Hepatology

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial

Jean-Frederic Colombel et al.

GASTROENTEROLOGY (2007)

Article Gastroenterology & Hepatology

Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry

GR Lichtenstein et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)

Article Gastroenterology & Hepatology

Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab

KA Papadakis et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)

Article Gastroenterology & Hepatology

Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease

P Rutgeerts et al.

GASTROENTEROLOGY (2004)

Article Gastroenterology & Hepatology

A pilot study of adalimumab in infliximab-allergic patients

A Youdim et al.

INFLAMMATORY BOWEL DISEASES (2004)

Article Gastroenterology & Hepatology

Long-term evolution of disease behavior of Crohn's disease

J Cosnes et al.

INFLAMMATORY BOWEL DISEASES (2002)

Article Medicine, General & Internal

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

SB Hanauer et al.

LANCET (2002)